AA
SABSW icon

AQR Arbitrage’s SAB Biotherapeutics Warrant SABSW Stock Holding History

AQR Arbitrage’s Portfolio SABSW Stock Details SABSW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-50,000
Closed -$45K – 1253
2021
Q3 		$45K Hold
50,000
– – ﹤0.01% 932
2021
Q2 		$46K Hold
50,000
– – ﹤0.01% 960
2021
Q1 		$30K Buy
+50,000
New +$51.9K ﹤0.01% 937

Other funds holding SABSW

SCM
Shaolin Capital Management Miami, Florida $2.71B AUM 64.83% 1-Year Est. Return
RCM
Radcliffe Capital Management Bala Cynwyd, Pennsylvania $1.33B AUM 1.18% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
YCM
Yakira Capital Management Westport, Connecticut $342M AUM 26.97% 1-Year Est. Return
LP
LMR Partners London, United Kingdom $45.4B AUM 60.68% 1-Year Est. Return
CH
CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return
ICMH
Integrity Capital Management (HK) Central, Hong Kong $64K AUM
MS
Maven Securities St Helier, Jersey $5.2B AUM 44.01% 1-Year Est. Return
RCM
Rivernorth Capital Management West Palm Beach, Florida $2B AUM 0.66% 1-Year Est. Return
EPM
Equitec Proprietary Markets Chicago, Illinois $559M AUM 230.29% 1-Year Est. Return

AQR Arbitrage's SABSW Position: Q4 2021 in Review

AQR Arbitrage sold out of SAB Biotherapeutics Warrant (SABSW) in Q4 2021, closing a stake of 50,000 shares — an estimated $45K sold.

AQR Arbitrage first reported a position in SABSW in Q1 2021 and held it in 3 quarters. The position peaked at $46K in Q2 2021. 21 funds tracked by Wall St. Rank hold SABSW as of Q4 2021.

  • AQR Arbitrage reported no remaining SAB Biotherapeutics Warrant position as of Q4 2021 after selling out during the quarter.
  • AQR Arbitrage sold 50,000 SAB Biotherapeutics Warrant shares in Q4 2021, an estimated $45K.
  • AQR Arbitrage first reported a position in SAB Biotherapeutics Warrant in Q1 2021 and held it in 3 quarters.
  • AQR Arbitrage's SAB Biotherapeutics Warrant position peaked at $46K in Q2 2021.
  • 21 funds tracked by Wall St. Rank held SAB Biotherapeutics Warrant as of Q4 2021.

Based on AQR Arbitrage's 13F filing for Q4 2021, filed 14 Feb 2022.